Latest Biotech News

Eli Lilly reported positive cardiovascular safety results for Foundayo (orforglipron) in a Phase III outcomes trial in adults with type 2 diabetes and obesity or overweight at increased...

Roche laid out a new Phase III trial plan for Elevidys (delandistrogene moxeparvovec), aiming to address lingering European regulatory questions after prior trial performance issues. The company...

Revolution Medicines reported a survival benefit from a Phase III trial of daraxonrasib (RMC-6236), an investigational RAS-targeting therapy in metastatic pancreatic ductal adenocarcinoma. In the...

Gilead Sciences disclosed new patent information covering GTPase KRAS G12D mutant inhibitors designed for cancer treatment. The filing points to an extension of Gilead’s small-molecule oncology...

UCB agreed to buy Neurona for up to $1.2 billion, expanding its pipeline with a potentially one-off cell therapy for a form of epilepsy that remains difficult to treat. UCB’s deal comes as the...

Beeline Medicines launched with five programs licensed from Bristol Myers Squibb and secured a $300 million Series A led by Bain Capital. The company’s portfolio is built around therapies for...

The U.S. FDA accepted and granted priority review to Daiichi Sankyo and Merck & Co.’s B7-H3-directed antibody-drug conjugate, ifinatamab deruxtecan, for advanced extensive-stage small-cell lung...

Biopharma layoffs slowed year over year in Q1 2026, but total affected employees rose, largely driven by company-specific cut plans. BioSpace tallied 35 biopharma companies making or projecting...

Revolution Medicines’ pan-RAS inhibitor daraxonrasib delivered a major survival benefit in its Phase 3 RASolute 302 trial for metastatic pancreatic ductal adenocarcinoma, beating standard...

UCB agreed to acquire Neurona Therapeutics for up to $1.2 billion, betting that a seizure cell-therapy platform can broaden its largely small-molecule epilepsy portfolio. UCB said the acquisition...

Roche announced it will initiate another global Phase 3 trial for Duchenne muscular dystrophy gene therapy Elevidys, aiming to generate data that could support an updated European...

Eli Lilly reported positive top-line results from a cardiovascular outcomes trial of Foundayo (orforglipron), meeting the study’s heart safety objective versus insulin glargine in adults with type...

Two separate policy signals emerged from FDA-facing coverage: the agency is moving toward easing restrictions on certain compounded peptides while also setting out a policy agenda that would make...

Storm Therapeutics closed a $56 million Series C to advance STC-15, its METTL3-targeting RNA enzyme inhibitor, through Phase 2 development in sarcoma. The company said the financing will support...

Neomorph secured a $100 million Series B financing round to advance NEO-811, an oral molecular glue degrader targeting ARNT (HIF-1β), through its Phase I/II trial in clear cell renal cell...

University of Cambridge-led researchers reported a targeted gene-delivery approach that calms lung inflammation during respiratory infection in mouse models by locally expressing immunomodulatory...

Alamar Biosciences began trading on Nasdaq after pricing its initial public offering of 12.94 million shares at $17 each, raising gross proceeds of about $220 million for its Argo HT platform and...

Kailera Therapeutics priced a record-setting upsized IPO, raising $625 million gross to fund late-stage development of its injectable and oral obesity pipeline, including ribupatide (KAI-9531)...

Kailera Therapeutics priced an upsized IPO that raised $625 million to fund its obesity pipeline, following earlier Series A/B rounds. The offering sets a new benchmark for US biopharma IPOs as...

Roche’s Foundation Medicine agreed to acquire Saga Diagnostics for up to $595 million, aiming to expand its cancer molecular residual disease (MRD) diagnostics portfolio. The deal adds Saga’s...